Initial Experience of (68)Ga PSMA PET/CT Imaging in High risk Prostate Cancer Patients Prior to Radical Prostatectomy.
UNLABELLED Prostate specific membrane antigen (PSMA) overexpression theoretically enables targeting of prostate cancer (PCa) metastases using gallium Ga 68 (68)Ga) labeled PSMA ligands for positron emission tomography/computed tomography (PET/CT) imaging. Promising detection rates have been reported when using this approach for functional imaging of recurrent PCa; however, until now, the diagnostic accuracy of (68)Ga PSMA PET/CT for preoperatively identifying lymph node metastases (LNMs) had not been assessed. We retrospectively compared preoperative (68)Ga PSMA PET/CT lymph node (LN) findings with histologic work up after radical prostatectomy (RP) Overall, 608 LNs containing 53 LNMs were detected during RP. LNMs were present in 12 of 30 patients (40% The (68)Ga PSMA PET/CT scans identified 4 patients (33.3% as LN true positive and 8 patients (66.7% as false negative. Median size of (68)Ga PSMA PET/CT detected versus undetected LNMs was 13.6 versus 4.3 mm (p<0.05) Overall sensitivity, specificity, positive predictive value, and negative predictive value of (68)Ga PSMA PET/CT for LNM detection were 33.3% 100% 100% and 69.2% respectively. Per side analyses revealed corresponding values of 27.3% 100% 100% and 52.9% Conversely, (68)Ga PSMA PET/CT enabled tumor visualization in the prostate. In 92.9% of patients, the intraprostatic tumor foci were correctly predicted. Overall, (68)Ga PSMA PET/CT is a promising tool for functional imaging; however, our initial experience revealed substantial influence of LNM size on the diagnostic accuracy of (68)Ga PSMA PET/CT. PATIENT SUMMARY We assessed the diagnostic accuracy of (68)Ga PSMA PET/CT in high risk prostate cancer patients prior to radical prostatectomy. We found that lymph node metastasis detection rates were substantially influenced by lymph node metastasis size.
European urology